Latest 30 News in the Life Sciences Industry
GlobeNewswire
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
11 Jun 2026
GlobeNewswire
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
11 Jun 2026
GlobeNewswire
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
11 Jun 2026
PR Newswire Association LLC.
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
11 Jun 2026
PR Newswire Association LLC.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
11 Jun 2026
GlobeNewswire
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
11 Jun 2026
GlobeNewswire
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
11 Jun 2026
GlobeNewswire
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
11 Jun 2026
PR Newswire Association LLC.
Sobi to present new clinical and real-world data at EHA 2026 in Stockholm
11 Jun 2026
GlobeNewswire
Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
11 Jun 2026
GlobeNewswire
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
10 Jun 2026
PR Newswire Association LLC.
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
10 Jun 2026
GlobeNewswire
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
10 Jun 2026
GlobeNewswire
Data Published in Interventional Pain Medicine Indicates Participants Who Received SPRINT PNS as Prescribed Were Three Times More Likely to Achieve Meaningful Pain Relief
10 Jun 2026
GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
10 Jun 2026
PR Newswire Association LLC.
HERVolution Therapeutics Demonstrates Preclinical Proof-of-Concept for Insulin Sensitization Immune Therapy in Metabolic Disease and Announces Exclusive License Agreement with the University of Copenhagen
10 Jun 2026
PR Newswire Association LLC.
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
10 Jun 2026
GlobeNewswire
BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback
09 Jun 2026
GlobeNewswire
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
09 Jun 2026
PR Newswire Association LLC.
Study that highlights Nevisense potential for prediction of AD published in leading journal
09 Jun 2026
PR Newswire Association LLC.
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
08 Jun 2026
PR Newswire Association LLC.
Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
08 Jun 2026
PR Newswire Association LLC.
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
07 Jun 2026
PR Newswire Association LLC.
Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
06 Jun 2026
PR Newswire Association LLC.
Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
06 Jun 2026
Upcoming Events All Events
- June 2026
- San Diego: RESI San Diego 2026
- San Diego: BIO 2026
- July 2026
- Taipei: BIO Asia-Taiwan